Metabolic modulation with metformin to reduce heart failure after acute myocardial infarction: Glycometabolic Intervention as adjunct to Primary percutaneous coronary intervention in ST elevation myocardial infarction (GIPS-III) - metformin to reduce heart failure after acute myocardial infarction

niversitair Medisch Centrum Groningen0 个研究点目标入组 380 人开始时间: 待定最近更新: 2024年5月6日

适应症

试验速览

暂无简介。

•Inclusion criteria are:
•- The diagnosis acute MI defined by chest pain suggestive for myocardial ischemia for at least 30 minutes, the time from onset of the symptoms less than 6 hours before hospital admission, and an ECG recording with ST- segment elevation of more than 0.1 mV in 2 or more leads.
•- First myocardial infarction;
•- Successful primary PCI (TIMI 2/3);
•- At least one stent sized >= 3.0 mm;
•- Eligible for CMR imaging;
•- BMI<40;
•- no claustrofobia;
•- no pacemaker, ICD, etc;
•- Informed consent.

•exclusion criteria are:
•- Rescue PCI after thrombolytic therapy;
•- Need for emergency coronary artery bypass grafting;
•- Inability to provide informed consent;
•- Younger than 18 years old;
•- Previous documented myocardial infarction;
•- Artificial breathing support;
•- Diabetes mellitus;
•- Algemene toestand van de patient die, op basis van de klinische inschatting van de behandeld arts en/of de onderzoeker, niet toestaat dat de patient deelneemt aan deze studie. General condition which, according to the clinical judgment of the investigator and/or treating physician, does not allow the patient to participate in the study
•- Contra-indication to metformin (see safety);
•- The existence of a life-threatening disease with a life-expectancy of less than 6 months.

发起方